Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... YORK (PRWEB) , ... August 03, 2020 , ... ... health and science innovations, today announced that Donna L. LaVoie, President, CEO and Founder ... in the life-sciences industry. , Since 2005, the PharmaVOICE 100 has honored more ...
(Date:7/31/2020)... (PRWEB) , ... July 31, 2020 , ... ... in partnership with Netquest, a global panel and data collection provider, recently released ... 1502 adults, across the United Kingdom, Germany and France. , “COVID-19 continues to ...
(Date:7/22/2020)... ... July 22, 2020 , ... Local animal nutrition expert, Dr. Anoosh Rakhshandeh, ... new pet food and supplies company – Pet Wants Lubbock. , Pet Wants’ specially-crafted, ... with vitamins and minerals for a complete and balanced diet in every bite. Pet ...
Breaking Medicine Technology:
(Date:8/7/2020)... ... August 07, 2020 , ... Mary J's Cannabis , Kingston’s premium recreational ... dicentra Cannabis Consulting . , The store, which operates out of a 100-year-old ... of many locations as the company plans to expand across Canada. , “At ...
(Date:8/5/2020)... ... August 05, 2020 , ... In ... risen to unprecedented challenges. Regardless of the obstacle - shortages of tests, ventilators ... (PPE) and the cancellation or postponement of all nonessential services - providers across ...
(Date:8/5/2020)... , ... August 05, 2020 , ... CentrAlert, Inc. ... help everyone gain access to essential COVID-19 information. Know NOW!, which is available for ... COVID-19 updates and unify them in one easy-to-use mobile application. , “When COVID-19 first ...
(Date:8/5/2020)... ... August 04, 2020 , ... Today, Power to Decide’s One Key Question ... the 2020 Innovation Station Best Practice Award. The One Key Question program is a ... get pregnant and have a child. One Key Question is used by thousands of ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... enrollment of the first patients with first-line advanced pancreatic cancer in a phase ... 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule ...
Breaking Medicine News(10 mins):